Modeled urea distribution volume and mortality in the HEMO Study

Clin J Am Soc Nephrol. 2011 May;6(5):1129-38. doi: 10.2215/CJN.06340710. Epub 2011 Apr 21.

Abstract

Background and objectives: In the Hemodialysis (HEMO) Study, observed small decreases in achieved equilibrated Kt/V(urea) were noncausally associated with markedly increased mortality. Here we examine the association of mortality with modeled volume (V(m)), the denominator of equilibrated Kt/V(urea).

Design, setting, participants, & measurements: Parameters derived from modeled urea kinetics (including V(m)) and blood pressure (BP) were obtained monthly in 1846 patients. Case mix-adjusted time-dependent Cox regressions were used to relate the relative mortality hazard at each time point to V(m) and to the change in V(m) over the preceding 6 months. Mixed effects models were used to relate V(m) to changes in intradialytic systolic BP and to other factors at each follow-up visit.

Results: Mortality was associated with V(m) and change in V(m) over the preceding 6 months. The association between change in V(m) and mortality was independent of vascular access complications. In contrast, mortality was inversely associated with V calculated from anthropometric measurements (V(ant)). In case mix-adjusted analysis using V(m) as a time-dependent covariate, the association of mortality with V(m) strengthened after statistical adjustment for V(ant). After adjustment for V(ant), higher V(m) was associated with slightly smaller reductions in intradialytic systolic BP and with risk factors for mortality including recent hospitalization and reductions in serum albumin concentration and body weight.

Conclusions: An increase in V(m) is a marker for illness and mortality risk in hemodialysis patients.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Biomarkers / blood
  • Blood Pressure
  • Female
  • Follow-Up Studies
  • Humans
  • Kidney Failure, Chronic / metabolism*
  • Kidney Failure, Chronic / mortality*
  • Kidney Failure, Chronic / therapy
  • Male
  • Middle Aged
  • Models, Biological
  • Predictive Value of Tests
  • Quality of Life
  • Renal Dialysis / methods*
  • Renal Dialysis / mortality*
  • Risk Adjustment
  • Risk Factors
  • Urea / blood*

Substances

  • Biomarkers
  • Urea